While Zomedica's loss per share has decreased, indicating some operational improvement, the significant miss in revenue expectations is likely to concern investors. Revenue is a critical measure of a company's growth and performance, and missing analyst estimates often leads to negative short-term price action as it may signal underlying issues with sales growth or market penetration.